Skip to main content
. 2021 May 16;57(5):503. doi: 10.3390/medicina57050503

Table 3.

Sensitivity, specificity, positive predictive value, and negative predictive value of PSAD ≥ 0.08 ng/mL/cc for clinically significant prostate cancer in 2162 subjects with varying disease prevalence.

Hypothetical Population (n = 2162) with 50% Disease Prevalence
Disease Positive Disease Negative Row Total Predictive Values
PSAD Positive 1059 908 1967 (↑) PPV = 1059/1967 (54%)
PSAD Negative 22 173 195 (↓) NPV = 173/195 (89%)
Column Total 1081 1081
SN = 1059/1081 (98%) SP = 173/1081 (16%)
Actual Study Population (23% Disease Prevalence, 98% Sensitivity, 16% Specificity) (n = 2162)
Disease Positive Disease Negative Row Total Predictive Values
PSAD Positive 489 1400 1889 PPV = 489/1889 (26%)
PSAD Negative 10 263 273 NPV = 263/273 (96%)
Column Total 499 1663
SN = 489/499 (98%) SP = 263/1663 (16%)
Hypothetical Population (n = 2162) with 10% Disease Prevalence
Disease Positive Disease Negative Row Total Predictive Values
PSAD Postive 212 1635 1847 (↓) PPV = 212/1847 (11%)
PSAD Negative 4 311 315 (↑) NPV = 311/315 (99%)
Column Total 216 1946
SN = 212/216 (98%) SP = 311/1946 (16%)

Note: Abbreviations—NPV, negative predictive value; PPV, positive predictive value; PSAD, prostate-specific antigen density; SN, sensitivity; SP, specificity.